www.urologiepropraxi.cz / Urol. praxi. 2023;24(2):58-63 / UROLOGIE PRO PRAXI 63 PŘEHLEDOVÉ ČLÁNKY Intravezikální termochemoterapie – indikace, příprava pacienta a praktické aspekty podání nádorů či jinak specifikovaného rozšíření indikačních kritérií. Od roku 2022 jsou metody HIVEC a RITE pro indikované pacienty v ČR dostupné a hrazené z prostředků veřejného zdravotního pojištění a přibývají tak reálné klinické zkušenosti z pracovišť, kde se využívají. Není tedy důvod této možnosti u vybraných pacientů nevyužít. Podpořeno MZ ČR – RVO (FNBr, 65269705). LITERATURA 1. Babjuk M, Burger M, Compérat E, et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). In: EAU Guidelines. Edn. presented at the EAU Annual Congres Amsterdam 2022. Arhhem, The Netherlands: EAU Guidelines Office; 2022:1-58. 2. Brausi M, Oddens J, Sylvester R, Bono A, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69-76. 3. Pang KH, Noon AP. Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer. Transl Androl Urol. 2019; 8(1):101-107. 4. Horňák J, Brisuda A, Babjuk M. Selhání intravezikální BCG imunoterapie v terapii svalovinu neinvadujících nádorů močového měchýře – současnost a budoucnost léčby. Rozhl Chir. 2022;101(3):108-113. 5. Hendricksen K. Device-assisted intravesical therapy for non-muscle invasive bladder cancer. Transl Androl Urol. 2019;8(1):94-100. 6. Brisuda A. Nové možnosti intravezikální instilační terapie u karcinomu močového měchýře. Ces Urol. 2018;22(4):251-256. 7. Kuncová J. Intravezikální, radiofrekvencí indukovaná chemohypertermie v léčbě svalovinu neinfiltrujících nádorů močového měchýře. Ces Urol. 2022;26(3):174-185. 8. Melgarejo-Segura MT, Morales-Martínez A, Yáñez- -Castillo Y, et al. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer. Urol Oncol. 2022, doi: 10.1016/j.urolonc.2022.09.016. Online ahead of print. 9. Tan WP, Chang A, Brousell SC, et al. Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. Int J Hyperthermia. 2020;37(1):854-860. 10. Seznam zdravotních výkonů. Registrační list – 76532 [online]. Praha: ÚZIS ČR, © 2016 [cit. 31-1-2023]. Available from: http://szv.mzcr.cz/Vykon/Detail/76532. 11. Plata A, Guerrero-Ramos F, Garcia C, González-Díaz A, et al. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain. J Clin Med. 2021;10(21):5105. 12. Angulo JC, Álvarez-Ossorio JL, Domínguez JL, et al. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2022, doi: 10.1016/j.euo.2022.10.008. Online ahead of print. 13. Tan WS, Prendergast A, Ackerman C, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. 2022. doi: 10.1016/j.eururo.2022.08.003. Online ahead of print. 14. Guerrero-Ramos F, González-Padilla DA, et al. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol. 2022;40(4):999-1004. 15. Pijpers OM, Hendricksen K, Mostafid H, et al. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urol Oncol. 2022;40(2):62. 16. Stemberger A, Tan WP, Bello AP, et al. A multicenter study of 2-year outcomes following hyperthermia therapy with Mitomycin C in treating BCG unresponsive non-muscle invasive bladder cancer: recirculant hyperthermic intravesical chemotherapy. J Urol. 2022;207(5):E932. 17. van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):351-362. 18. Seznam zdravotních výkonů. Registrační list – 76534 [online]. Praha: ÚZIS ČR, © 2016 [cit. 31-1-2023]. Available from: http://szv.mzcr.cz/Vykony/Detail/76534. 19. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003; 21(23):4270-4276. 20. Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011; 107(6):912-918. 21. Arends TJ, Nativ O, Maffezzini M, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol. 2016;69(6):1046-1052. 22. Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette- -Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Eur Urol. 2019;75(1):63-71. 23. Witjes JA. Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need? Eur Urol. 2019;75(1):72-73. 24. Brummelhuis ISG, Wimper Y, Witjes-van Os HGJM, et al. Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. Cancers. 2021;13(3):377. 25. Babjuk M. Re: Long-term Experience with Radiofrequency-induced Hyperthermia Combined with Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer. Eur Urol. 2022;81(5):541. 26. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011;60(1):81-93. Využíváme systém CrossRef. S články můžete snadno pracovat díky jednoznačnému identi kátoru DOI. S NÁMI SE NEZTRATÍTE Časopis je indexován v databázi EBSCO
RkJQdWJsaXNoZXIy NDA4Mjc=